I think is is way to early for a takeover at a reasonable share price that the shareholders would accept.
I am thinking that if the FDA has had visibility of the PMS Phase 2 results and they have similar efficacy as the pre-clinical mouse studies, then I am wondering if the FDA may have suggested a fast path for NNZ-2591 to get to PMS patients asap / quicker than planned. I am hoping this will be discussed on Monday as they results are announced.
I think is is way to early for a takeover at a reasonable share...
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.00 |
Change
0.090(0.45%) |
Mkt cap ! $2.556B | |||
| Open | High | Low | Value | Volume |
| $19.88 | $20.07 | $19.73 | $11.80M | 591.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5901 | $19.97 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.00 | 3262 | 5 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |